Aktiekursudvikling

WntResearch: Closer Than Ever

Case: WntResearch Closer than ever WntResearch has applied for their phase II trials regarding proof-of-concept for the FOXT-5 compound. Hence, WntResearch is closer than ever

Læs mere »

Disclaimer

Kapital Partner udfører eller har inden for de seneste 12 måneder udført corporate finance, market relations, investor relations, Certified Adviser eller andre rådgivningsaktiviteter for følgende børsnoterede selskaber: Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.